Your web browser is out of date! We recommend you update your browser to receive the best possible browsing experience.

Co-located with our

COMMERCIAL EXCELLENCE SUMMIT

2018 Conference Agenda

7:30
-
8:30
REGISTRATION
8:30
-
8:35
WELCOME FROM ORGANIZER
Opening Keynote Session
8:35
-
9:05
Patient Engagement at a pharmaceutical company – Case studies at UCB Japan
  • History of “Patient Centricity” at UCB Japan
  • Evolution from “Patient Centricity” to “Patient Value Strategy” as UCB’s Global Strategy
  • Case studies at UCB Japan: a patient value mind-set at all levels of the organisation – current challenges and future

UCB Japan Co., Ltd. Satoshi Miki Japan Representative Director, Vice President, Head of CoE Strategy & Planning for East Asia Region UCB Japan Co., Ltd.

9:05
-
9:50
Overcome pricing challenges: ensure your model demonstrates and communicates your true product value
  • Prepare to show exactly how your product provides improved long-term value to the Japanese market in order to tackle the pricing challenges
  • Meet the requirements of upcoming healthcare policy, and find how you can help and support the Japanese healthcare system

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. Chairman and Representative Director Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim Animal Health Japan Co., Ltd.
Boehringer Ingelheim Seiyaku
Vice Chairman EFPIA-Japan

9:50
-
10:20
The Act on the Next-Generation Medical Infrastructure
  • To grasp the overview of "The Act on the Next-Generation Medical Infrastructure" promulgated for the realization of advanced and efficient medical care through the utilization of medical ICT.
  • To understand the impact of "The Act on the Next-Generation Medical Infrastructure" on research and business environment surrounding pharmaceutical companies.

Councillor, Cabinet Secretariat, Government of Japan Koji Fujimoto Deputy Director-General, Office of Healthcare Policy Councillor, Cabinet Secretariat, Government of Japan

10:20
-
11:05
COFFEE BREAK
See what’s possible
Explore the rich opportunities and challenges for your company over the next few years
11:05
-
11:35
Use RWD to become a real ‘corporate citizen’ by measuring and improving your contribution to the health of local communities and society at large
  • Contribute to society by understanding the real demand – in particular, find unmet medical needs from good quality RWD
  • Determine the value you provide to society – measure the outcomes from RWE

Keio University Hiroaki Miyata Professor, Department of Health Policy and Management School of Medicine Keio University

11:35
-
12:05
Establish good use of RWE as an essential capability for your company – and see how improving analysis will improve your medical affairs, PV, market access and marketing functions
  • Understand exactly how RWE utilization will enhance functions such as Medical Affairs, Pharmacovigilance and Market Access in the next 2 years
  • Appreciate the importance of how RWE will allow you to differentiate your product and your corporate brand in a meaningful way

Pfizer Japan Inc. Yasuyuki Katayama Corporate Officer, Country Medical Director and Head of Medical Japan Pfizer Japan Inc.

12:15
-
13:00
WORKSHOP (CMIC & MILLIMAN)
13:00
-
14:05
LUNCH
Create access to the real world
A spotlight on some of the newest RWD opportunities and their applications
14:05
-
14:35
See how multi-lateral use of electronic clinical data was achieved with the millennium medical record project
  • Witness the collection of clinical data from approximately 200 hospitals to establish a large and fit-for-purpose database
  • Real name use: to enable cooperative medical treatment, see how the disclosure of clinical data to patients was managed
  • How to ensure anonymity and privacy when using statistical data for research-only applications

kyoto_university Hiroyuki Yoshihara Emeritus professor
Director of the Department for EHR Research, Graduate School of Medicine
Kyoto University Emeritus professor
Distinguished Professor of the Centre for EHR, University Hospital Miyazaki
University of Miyazaki

14:35
-
15:05
Can your company meet the ‘real’ need for real world evidence? Examine the actions required from drug discovery to marketing
  • An evaluation of the most impactful areas which RWE can make a difference in
  • Beyond RWE: Explore the rationale for utilizing artificial intelligence (AI) in your company
  • Real use cases for deploying AI/IoT initiatives in your company

Eisai Co.,Ltd. Hiroyuki Kobayashi Vice President, Chief Medical Officer Japan/Asia
Medical Headquarters
Eisai Co.,Ltd.

15:05
-
15:35
Make the use of RWD the foundation of your company
  • Learn more about the RWD sourced from vendors: appreciate its utility and role in different parts of your company. And understand how the realities of medical treatment in the real world are translated into data
  • Examine the limits of RWD, including where only a part of the outcomes are covered - and determine solutions to these limitations
  • Raise your awareness of technological trends in RWD, and how you should plan in your company

IMS Japan K.K. Nobutomo Matsui Senior Principal
Real World Insights
IMS Japan K.K.

13:00
-
14:05
COFFEE BREAK
Make it happen
Maximize the pot entail of your RWE studies
16:05
-
16:35
Improve the planning and execution of database research conducted by Medical Affairs - see real examples
  • What should be kept in mind when planning protocols for database research?
  • How to ensure transparency and reliability when conducting database research
  • What are the points to consider when posting database research to peer review journal?

MSD K.K. Shinichi Kanazu Director, Medical Research Project Management,
Medical Affairs
MSD K.K.

16:35
-
17:05
Create a market access strategy for enhancing product values with use of varied study designs and outcome measures
  • Understand the different types of important health outcome measurements and how to select the appropriate one
  • Develop strategy for choosing your optimal study design and outcomes, depending on research questions
  • Examples of how to incorporate patient centric data, in particular Patient Reported Outcomes (PROs)

Bayer Yakuhin, Ltd. Nariaki Yoshihara Head of Health Economics & Outcomes Research
Market Access, Health Economics & Outcomes Research
Bayer Yakuhin, Ltd.

17:05
-
17:50
PANEL DISCUSSION
How can we reinforce our internal infrastructure for RWE adoption? – discuss the regulatory, data capture and company strategy perspectives
  • Discuss the ideal organizational conditions for getting the most of RWE
  • How should senior-level executives support RWE initiatives and evaluate their utility?
  • How should pharmaceuticals collaborate with regulators, academia and other external stakeholders to further the industry’s quest to produce real value

Naoya Horiuchi Director Office of Healthcare Policy,
Cabinet Secretariat, Government of Japan

kyoto_university Hiroyuki Yoshihara Emeritus professor
Director of the Department for EHR Research, Graduate School of Medicine
Kyoto University Emeritus professor
Distinguished Professor of the Centre for EHR, University Hospital Miyazaki
University of Miyazaki

Eisai Co.,Ltd. Hiroyuki Kobayashi Vice President, Chief Medical Officer Japan/Asia
Medical Headquarters
Eisai Co.,Ltd.

MSD K.K. Rick Tsai Executive Officer, Head of Medical Affairs MSD K.K.

17:50
-
19:30
NETWORKING DRINKS
8:00
-
9:00
REGISTRATION
9:00
-
9:30
The Mission of AMED: Meeting the challenge of global data-sharing
  • A look at the “Initiative for Rare and Undiagnosed Diseases (IRUD)” as AMED’s leading project
  • Understand a number of the obstacles faced, including the “Balkanization” of mindsets among academia and researchers in a field of rare diseases
  • An overview of whether the project mission was achieved - and key learnings in data sharing in medical innovations.
  • An introduction to novel projects including the harnessing of medical ICT networks

Japan Agency for Medical Research and Development Makoto Suematsu President Japan Agency for Medical Research and Development

Successful implementation
Ensure the right RWE study for the right application
9:30
-
10:00
Drugs for pre-symptom cures: how to use an ‘estimation engine’ from health indexes and disease risk to prevent poor outcomes
  • Analyse the invisible path from pre-symptom to disease
  • Find the correlation between a patient’s health index and disease-risk to minimise becoming ill
  • Big Data Analysis – a look at the process and design behind differentiating between healthy individuals and individuals with pre-symptoms

AXION RESEARCH INC. Tomo Sato President & CEO
Business Management Strategy Office
AXION RESEARCH INC.

10:00
-
10:30
How does RWE improve our understanding of disease?
  • Compare clinical trials and RWE – do they conflict or compliment? Together, do they confuse or construct a better understanding?
  • Disease examples which demonstrate the true value of RWE

Takeda Pharmaceutical Company Limited Jovelle Fernandez Japan Medical Officer, Head of Japan Medical Affairs
Japan Medical Affairs, Japan Pharma Business Unit
Takeda Pharmaceutical Company Limited

10:30
-
11:00
COFFEE BREAK
11:00
-
11:30
RWD does not like RWE! How to overcome the weak points in creating evidence
  • Examine the change of regulatory requirements within Japanese pharmacovigilance
  • How RWD can increase the credibility of outcomes by filling the gaps
  • How to compare multiple treatments to evaluate the success of one evidence initiative

Chugai Pharmaceutical Co.,Ltd. Kotonari Aoki Department Manager
Real World Data Science Dept.
Chugai Pharmaceutical Co.,Ltd.

Into the future
Understand the newest applications of RWE and how it can improve the trajectory of your company in a value-based health economy
11:30
-
12:00
Create transformation through RWD
  • Prove the essential value of RWD
  • Introduce ways on how to solve issues which has never been solved by a traditional method through IBM case studies

IBM Japan Tatsuya Kaneko Partner, Life Sciences/Pharma Japan Industry Lead
IBM Global Business Services, IBM Services
IBM Japan

12:00
-
13:15
LUNCH
13:15 - 13:45
RWE and Health Technology Assessment: What have we learnt from Japan’s Pilot Program?
  • Introduction to HTA
  • Utilising RWE in HTA
  • Reality in Japan’s HTA pilot program

Amgen Astellas BioPharma K.K. Kenji Adachi Head
Value, Access & Policy, Health Economics & Outcomes Research
Amgen Astellas BioPharma K.K.

13:45
-
14:15
Expand your horizons by understanding the RWE trends in US/Europe – and learn the lessons you can apply to Japan
  • Witness updates about regulations covering data use in US and Europe which you can apply locally
  • Successful examples of smart RWE use in other countries which will affect your Japanese approach
  • A look at some popular and useful RWD sources in US and Europe that may be emerging soon in Japan

GlaxoSmithKline Japan Katsiaryna Holl Head Vaccines Health Outcomes
Clinical Platform and Sciences department
GlaxoSmithKline Japan

14:15
-
15:00
PANEL DISCUSSION
How should the wider healthcare industry change to align with the expanding utilization of RWE?
  • How to make sure HCPs understand the use of RWE in pharma – and the benefits for them through RWE
  • When real world data meets real world patients: understand how to control patient concerns and expectations
  • Envision the possible change in related industries: how will your current vendors change and influence your RWE strategy? Examine the implications for your business plan

AstraZeneca K.K. Stefan Woxström Representative Director and President AstraZeneca K.K.

AbbVie GK Susumu Amano Director
Market Access & External Relations
AbbVie GK

Eli Lilly Japan Shinichi Nishiuma Director, Safety medical and Epidemiology/ Database research Eli Lilly Japan

The Cardiovascular Institute Shinya Suzuki Medical Director
Department of cardiovascular medicine
The Cardiovascular Institute

15:00
-
15:30
COFFEE BREAK
Closing Keynote Session
15:30
-
16:00
Healthcare transformation through medical big data platform and future role of pharmaceutical companies
  • Introduce case examples on data collection and analysis of medical big data platform in Japan and the U.S.
  • Discuss future roles of pharma companies in community health transformation and R&D innovation for new drug development

PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

16:00
-
16:30
Get your talent formula right: optimize for effective leadership
  • Improving the work environment to boost business performance Purpose, inclusion and innovation
  • The era of internal collaboration: enabling co-operation across functions
  • Reward and recognition in for today's organizations

Novartis David Lennon Oncology General Manager Japan Novartis

EYEFORPHARMA JAPAN 2018 SPECIAL
-
PRESIDENT / CEO PANEL DISCUSSION
16:30
-
17:15
Pharma as the primary partner for improving Japanese healthcare
  • How our companies can form a new relationship with stakeholders and work on shared objectives to create the ideal patient model
  • Examples from other countries where similar partnerships have provided win-win-win-win situations for pharma, government, HCP and patients
  • Visualizations of Japanese healthcare in 2020 & 2025: How is your workforce going to change?

Company_Name Satoru Noguchi President Celgene K.K.

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Stefan Woxström Representative Director and President AstraZeneca K.K.

7:30
-
8:30
REGISTRATION
8:30
-
8:35
WELCOME FROM ORGANIZER
Opening Keynote Session
8:35
-
9:05
Patient Engagement at a pharmaceutical company – Case studies at UCB Japan
  • History of “Patient Centricity” at UCB Japan
  • Evolution from “Patient Centricity” to “Patient Value Strategy” as UCB’s Global Strategy
  • Case studies at UCB Japan: a patient value mind-set at all levels of the organisation – current challenges and future

UCB Japan Co., Ltd. Satoshi Miki Japan Representative Director, Vice President, Head of CoE Strategy & Planning for East Asia Region UCB Japan Co., Ltd.

9:05
-
9:50
Overcome pricing challenges: ensure your model demonstrates and communicates your true product value
  • Prepare to show exactly how your product provides improved long-term value to the Japanese market in order to tackle the pricing challenges
  • Meet the requirements of upcoming healthcare policy, and find how you can help and support the Japanese healthcare system

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Thorsten Poehl President and Representative Director Boehringer Ingelheim Japan, Inc. Chairman and Representative Director Nippon Boehringer Ingelheim Co., Ltd.
Boehringer Ingelheim Animal Health Japan Co., Ltd.
Boehringer Ingelheim Seiyaku
Vice Chairman EFPIA-Japan

9:50
-
10:20
The Act on the Next-Generation Medical Infrastructure
  • To grasp the overview of "The Act on the Next-Generation Medical Infrastructure" promulgated for the realization of advanced and efficient medical care through the utilization of medical ICT.
  • To understand the impact of "The Act on the Next-Generation Medical Infrastructure" on research and business environment surrounding pharmaceutical companies.

Councillor, Cabinet Secretariat, Government of Japan Koji Fujimoto Deputy Director-General, Office of Healthcare Policy Councillor, Cabinet Secretariat, Government of Japan

10:20
-
11:05
COFFEE BREAK
See what’s possible
Explore the rich opportunities and challenges for your company over the next few years
11:05
-
11:35
Use RWD to become a real ‘corporate citizen’ by measuring and improving your contribution to the health of local communities and society at large
  • Contribute to society by understanding the real demand – in particular, find unmet medical needs from good quality RWD
  • Determine the value you provide to society – measure the outcomes from RWE

Keio University Hiroaki Miyata Professor, Department of Health Policy and Management School of Medicine Keio University

11:35
-
12:05
Establish good use of RWE as an essential capability for your company – and see how improving analysis will improve your medical affairs, PV, market access and marketing functions
  • Understand exactly how RWE utilization will enhance functions such as Medical Affairs, Pharmacovigilance and Market Access in the next 2 years
  • Appreciate the importance of how RWE will allow you to differentiate your product and your corporate brand in a meaningful way

Pfizer Japan Inc. Yasuyuki Katayama Corporate Officer, Country Medical Director and Head of Medical Japan Pfizer Japan Inc.

12:15
-
13:00
WORKSHOP (CMIC & MILLIMAN)
13:00
-
14:05
LUNCH
Create access to the real world
A spotlight on some of the newest RWD opportunities and their applications
14:05
-
14:35
See how multi-lateral use of electronic clinical data was achieved with the millennium medical record project
  • Witness the collection of clinical data from approximately 200 hospitals to establish a large and fit-for-purpose database
  • Real name use: to enable cooperative medical treatment, see how the disclosure of clinical data to patients was managed
  • How to ensure anonymity and privacy when using statistical data for research-only applications

kyoto_university Hiroyuki Yoshihara Emeritus professor
Director of the Department for EHR Research, Graduate School of Medicine
Kyoto University Emeritus professor
Distinguished Professor of the Centre for EHR, University Hospital Miyazaki
University of Miyazaki

14:35
-
15:05
Can your company meet the ‘real’ need for real world evidence? Examine the actions required from drug discovery to marketing
  • An evaluation of the most impactful areas which RWE can make a difference in
  • Beyond RWE: Explore the rationale for utilizing artificial intelligence (AI) in your company
  • Real use cases for deploying AI/IoT initiatives in your company

Eisai Co.,Ltd. Hiroyuki Kobayashi Vice President, Chief Medical Officer Japan/Asia
Medical Headquarters
Eisai Co.,Ltd.

15:05
-
15:35
Make the use of RWD the foundation of your company
  • Learn more about the RWD sourced from vendors: appreciate its utility and role in different parts of your company. And understand how the realities of medical treatment in the real world are translated into data
  • Examine the limits of RWD, including where only a part of the outcomes are covered - and determine solutions to these limitations
  • Raise your awareness of technological trends in RWD, and how you should plan in your company

IMS Japan K.K. Nobutomo Matsui Senior Principal
Real World Insights
IMS Japan K.K.

13:00
-
14:05
COFFEE BREAK
Make it happen
Maximize the pot entail of your RWE studies
16:05
-
16:35
Improve the planning and execution of database research conducted by Medical Affairs - see real examples
  • What should be kept in mind when planning protocols for database research?
  • How to ensure transparency and reliability when conducting database research
  • What are the points to consider when posting database research to peer review journal?

MSD K.K. Shinichi Kanazu Director, Medical Research Project Management,
Medical Affairs
MSD K.K.

16:35
-
17:05
Create a market access strategy for enhancing product values with use of varied study designs and outcome measures
  • Understand the different types of important health outcome measurements and how to select the appropriate one
  • Develop strategy for choosing your optimal study design and outcomes, depending on research questions
  • Examples of how to incorporate patient centric data, in particular Patient Reported Outcomes (PROs)

Bayer Yakuhin, Ltd. Nariaki Yoshihara Head of Health Economics & Outcomes Research
Market Access, Health Economics & Outcomes Research
Bayer Yakuhin, Ltd.

17:05
-
17:50
PANEL DISCUSSION
How can we reinforce our internal infrastructure for RWE adoption? – discuss the regulatory, data capture and company strategy perspectives
  • Discuss the ideal organizational conditions for getting the most of RWE
  • How should senior-level executives support RWE initiatives and evaluate their utility?
  • How should pharmaceuticals collaborate with regulators, academia and other external stakeholders to further the industry’s quest to produce real value

Naoya Horiuchi Director Office of Healthcare Policy,
Cabinet Secretariat, Government of Japan

kyoto_university Hiroyuki Yoshihara Emeritus professor
Director of the Department for EHR Research, Graduate School of Medicine
Kyoto University Emeritus professor
Distinguished Professor of the Centre for EHR, University Hospital Miyazaki
University of Miyazaki

Eisai Co.,Ltd. Hiroyuki Kobayashi Vice President, Chief Medical Officer Japan/Asia
Medical Headquarters
Eisai Co.,Ltd.

MSD K.K. Rick Tsai Executive Officer, Head of Medical Affairs MSD K.K.

17:50
-
19:30
NETWORKING DRINKS

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription

8:00
-
9:00
REGISTRATION
9:00
-
9:30
The Mission of AMED: Meeting the challenge of global data-sharing
  • A look at the “Initiative for Rare and Undiagnosed Diseases (IRUD)” as AMED’s leading project
  • Understand a number of the obstacles faced, including the “Balkanization” of mindsets among academia and researchers in a field of rare diseases
  • An overview of whether the project mission was achieved - and key learnings in data sharing in medical innovations.
  • An introduction to novel projects including the harnessing of medical ICT networks

Japan Agency for Medical Research and Development Makoto Suematsu President Japan Agency for Medical Research and Development

Successful implementation
Ensure the right RWE study for the right application
9:30
-
10:00
Drugs for pre-symptom cures: how to use an ‘estimation engine’ from health indexes and disease risk to prevent poor outcomes
  • Analyse the invisible path from pre-symptom to disease
  • Find the correlation between a patient’s health index and disease-risk to minimise becoming ill
  • Big Data Analysis – a look at the process and design behind differentiating between healthy individuals and individuals with pre-symptoms

AXION RESEARCH INC. Tomo Sato President & CEO
Business Management Strategy Office
AXION RESEARCH INC.

10:00
-
10:30
How does RWE improve our understanding of disease?
  • Compare clinical trials and RWE – do they conflict or compliment? Together, do they confuse or construct a better understanding?
  • Disease examples which demonstrate the true value of RWE

Takeda Pharmaceutical Company Limited Jovelle Fernandez Japan Medical Officer, Head of Japan Medical Affairs
Japan Medical Affairs, Japan Pharma Business Unit
Takeda Pharmaceutical Company Limited

10:30
-
11:00
COFFEE BREAK
11:00
-
11:30
RWD does not like RWE! How to overcome the weak points in creating evidence
  • Examine the change of regulatory requirements within Japanese pharmacovigilance
  • How RWD can increase the credibility of outcomes by filling the gaps
  • How to compare multiple treatments to evaluate the success of one evidence initiative

Chugai Pharmaceutical Co.,Ltd. Kotonari Aoki Department Manager
Real World Data Science Dept.
Chugai Pharmaceutical Co.,Ltd.

Into the future
Understand the newest applications of RWE and how it can improve the trajectory of your company in a value-based health economy
11:30
-
12:00
Create transformation through RWD
  • Prove the essential value of RWD
  • Introduce ways on how to solve issues which has never been solved by a traditional method through IBM case studies

IBM Japan Tatsuya Kaneko Partner, Life Sciences/Pharma Japan Industry Lead
IBM Global Business Services, IBM Services
IBM Japan

12:00
-
13:15
LUNCH
13:15 - 13:45
RWE and Health Technology Assessment: What have we learnt from Japan’s Pilot Program?
  • Introduction to HTA
  • Utilising RWE in HTA
  • Reality in Japan’s HTA pilot program

Amgen Astellas BioPharma K.K. Kenji Adachi Head
Value, Access & Policy, Health Economics & Outcomes Research
Amgen Astellas BioPharma K.K.

13:45
-
14:15
Expand your horizons by understanding the RWE trends in US/Europe – and learn the lessons you can apply to Japan
  • Witness updates about regulations covering data use in US and Europe which you can apply locally
  • Successful examples of smart RWE use in other countries which will affect your Japanese approach
  • A look at some popular and useful RWD sources in US and Europe that may be emerging soon in Japan

GlaxoSmithKline Japan Katsiaryna Holl Head Vaccines Health Outcomes
Clinical Platform and Sciences department
GlaxoSmithKline Japan

14:15
-
15:00
PANEL DISCUSSION
How should the wider healthcare industry change to align with the expanding utilization of RWE?
  • How to make sure HCPs understand the use of RWE in pharma – and the benefits for them through RWE
  • When real world data meets real world patients: understand how to control patient concerns and expectations
  • Envision the possible change in related industries: how will your current vendors change and influence your RWE strategy? Examine the implications for your business plan

AstraZeneca K.K. Stefan Woxström Representative Director and President AstraZeneca K.K.

AbbVie GK Susumu Amano Director
Market Access & External Relations
AbbVie GK

Eli Lilly Japan Shinichi Nishiuma Director, Safety medical and Epidemiology/ Database research Eli Lilly Japan

The Cardiovascular Institute Shinya Suzuki Medical Director
Department of cardiovascular medicine
The Cardiovascular Institute

15:00
-
15:30
COFFEE BREAK
Closing Keynote Session
15:30
-
16:00
Healthcare transformation through medical big data platform and future role of pharmaceutical companies
  • Introduce case examples on data collection and analysis of medical big data platform in Japan and the U.S.
  • Discuss future roles of pharma companies in community health transformation and R&D innovation for new drug development

PwC Consulting LLC Yujiro Tsutsumi Managing Executive Director
Health Industries Advisory
PwC Consulting LLC

16:00
-
16:30
Get your talent formula right: optimize for effective leadership
  • Improving the work environment to boost business performance Purpose, inclusion and innovation
  • The era of internal collaboration: enabling co-operation across functions
  • Reward and recognition in for today's organizations

Novartis David Lennon Oncology General Manager Japan Novartis

EYEFORPHARMA JAPAN 2018 SPECIAL
-
PRESIDENT / CEO PANEL DISCUSSION
16:30
-
17:15
Pharma as the primary partner for improving Japanese healthcare
  • How our companies can form a new relationship with stakeholders and work on shared objectives to create the ideal patient model
  • Examples from other countries where similar partnerships have provided win-win-win-win situations for pharma, government, HCP and patients
  • Visualizations of Japanese healthcare in 2020 & 2025: How is your workforce going to change?

Company_Name Satoru Noguchi President Celgene K.K.

Company_Name Ole Mølskov Bech President and Representative Director Novo Nordisk Pharma Ltd. Chairman EFPIA-Japan

Company_Name Stefan Woxström Representative Director and President AstraZeneca K.K.

Purchase the Post-Conference Materials

Event Presentations • Event Audio • On Demand Subscription